Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.200
-0.050 (-4.00%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Immuron Revenue
Immuron had revenue of 4.18M AUD in the half year ending December 31, 2025, with 77.64% growth. This brings the company's revenue in the last twelve months to 7.48M, up 14.30% year-over-year. In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M with 48.63% growth.
Revenue (ttm)
7.48M AUD
Revenue Growth
+14.30%
P/S Ratio
1.96
Revenue / Employee
1,068,146 AUD
Employees
7
Market Cap
9.80M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.85M | -95.13% |
| Jun 30, 2020 | 2.99M | 604.81K | 25.33% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 6.50M |
| BioRestorative Therapies | 357.87K |
| Aprea Therapeutics | 123.30K |
| Jupiter Neurosciences | 40.45K |
| Kiora Pharmaceuticals | 20.00K |
| Ernexa Therapeutics | 1,000.00 |
IMRN News
- 6 weeks ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 7 weeks ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 3 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 3 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 4 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 5 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 6 months ago - Why Is Immuron Stock (IMRN) Down Today? - TipRanks
- 6 months ago - Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes - GuruFocus